# Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment

> **NCT00802568** · PHASE2 · COMPLETED · sponsor: **Institut Paoli-Calmettes** · enrollment: 48 (estimated)

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** busulfan
- **DRUG:** fludarabine phosphate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** nonmyeloablative allogeneic hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT00802568
- **Lead sponsor:** Institut Paoli-Calmettes
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2011-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00802568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00802568, "Fludarabine, Busulfan, Antithymocyte Globulin, and Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma That Has Not Responded to Treatment". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00802568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*